Usefulness of FSH measurements for determining menopause in long-term users of depot medroxyprogesterone acetate over 40 years of age

Contraception

Volumn 76, Issue 4, 2007, Pages 282-286

  Juliato, Cassia Teatin ^a   Fernandes, Arlete ^a   Marchi, Nadia Maria ^a   Castro, Sara ^a   Olivotti, Bruna ^a   Bahamondes, Luis ^a  

^a Department of Obstetrics and Gynecology School of Medicine Universida de Estadual de Campinas   (Brazil)

Author keywords

Depot medroxyprogesterone acetate; Follicle stimulating hormone; Menopause

Indexed keywords

FOLLITROPIN; MEDROXYPROGESTERONE ACETATE;

AMENORRHEA; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; FEMALE; HORMONE BLOOD LEVEL; HUMAN; LONG TERM EXPOSURE; MAJOR CLINICAL STUDY; POSTMENOPAUSE;

ADULT; AMENORRHEA; CONTRACEPTIVE AGENTS, FEMALE; FEMALE; FOLLICLE STIMULATING HORMONE; HUMANS; MEDROXYPROGESTERONE 17-ACETATE; MENOPAUSE; POSTMENOPAUSE; PROSPECTIVE STUDIES; REFERENCE VALUES;

EID: 34548853707     PISSN: 00107824     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.contraception.2007.06.005     Document Type: Article

References (27)

1. World Health Organization. Medical eligibility criteria for contraceptive use. 3rd ed. (2004), WHO Reproductive Health and Research, Geneva 1-14
2. Bahamondes L., Trevisan M., Andrade L., Marchi N.M., Castro S., Diaz J., et al. The effect upon the human vaginal histology of the long-term use of the injectable contraceptive Depo-Provera. Contraception 62 (2000) 23-27
3. Fraser I.S., and Weisberg E. A comprehensive review of injectable contraception with special emphasis on depot medroxyprogesterone acetate. Med J Aust 1 1 Suppl (1981) 3-19
4. Franchimont P., Cession G., Ayalon D., Mutsers A., and Legros J.J. Suppressive action of norethisterone enanthate and acetate on gonadotropin (FSH and LH) levels. Radioimmunoassay in eugonadal and postmenopausal women. Obstet Gynecol 36 (1970) 93-100
5. Fotherby K., Howard G., Shrimanker K., Elder M., and Bye P.G. Effect of norethisterone oenanthate on serum gonadotrophin levels. Contraception 16 (1977) 591-604
6. Perez Palacios G., Chavez B., Escobar N., Vilchis F., Larrea F., Lince M., et al. Mechanism of action of contraceptive synthetic progestins. J Steroid Biochem 15 (1981) 125-130
7. Beksinska M.E., Smit J.A., Kleinschmidt I., Rees H.V., Farley T.M., and Guidozzi F. Detection of raised FSH levels among older women using depomedroxyprogesterone acetate and norethisterone enanthate. Contraception 68 (2003) 339-343
8. Randolph Jr. J.F., Crawford S., Dennerstein L., Cain K., Harlow S.D., Little R., et al. The value of follicle-stimulating hormone concentration and clinical findings as markers of late menopausal transition. J Clin Endocrinol Metab 91 (2006) 3034-3040
9. Soules M.R., Sherman S., Parrott E., Rebar R., Santoro N., Utian W., et al. Executive summary: stages of Reproductive Aging Workshop (STRAW). Fertil Steril 76 (2001) 874-878
10. Morrison J.C., Martin D.C., Blair R.A., et al. The use of medroxyprogesterone acetate for relief of climacteric symptoms. Am J Obstet Gynecol 138 (1980) 99-104
11. Lobo R.A., McCormick W., Singer F., and Roy S. Depo-medroxyprogesterone acetate compared with conjugated estrogens for the treatment of postmenopausal women. Obstet Gynecol 63 (1984) 1-5
12. McKinlay S.M., Brambilla D.J., and Posner J.G. The normal menopause transition. Maturitas 14 (1992) 103-115
13. Shideler S.E., DeVane G.W., Kalra P.S., Benirschke K., and Lasley B.L. Ovarian-pituitary hormone interactions during the perimenopause. Maturitas 11 (1989) 331-339
14. Bastian L.A., Smith C.M., and Nanda K. Is this woman perimenopausal?. JAMA 289 (2003) 895-902
15. Burger H.G. The endocrinology of the menopause. J Steroid Biochem Mol Biol 69 (1999) 31-35
16. Burger H.G., Dudley E.C., Robertson D.M., and Dennerstein L. Hormonal changes in the menopause transition. Recent Prog Horm Res 57 (2002) 257-275
17. Perez-Palacios G., Fernandez-Aparicio M.A., Medina M., Zacarias-Villareal J., and Ulloa-Aguirre A. On the mechanism of action of progestins. Acta Endocrinol (Copenh) 97 (1981) 320-328
18. McDaniel E.B., and Pardthaisong T. Use of a long-acting injectable contraceptive in a post partum family planning programme. Asian Med J 9 (1973) 133-135
19. Schwallie P.C., and Assenzo J.R. The effect of depo-medroxyprogesterone acetate on pituitary and ovarian function, and the return of fertility following its discontinuation: a review. Contraception 10 (1974) 181-202
20. Kora S., and Virkar K. Incidence of pregnancy, changes in menstrual pattern, and recovery of endometrial function after discontinuation of medroxyprogesterone acetate therapy. Fertil Steril 26 (1975) 121-125
21. Pardthaisong T., Gray R.H., and McDaniel E.B. Return of fertility after discontinuation of depot medroxyprogesterone acetate and intra-uterine devices in Northern Thailand. Lancet 1 (1980) 509-512
22. Schwartz D., and Mayaux M.J. Female fecundity as a function of age: results of artificial insemination in 2193 nulliparous women with azoospermic husbands. Federation CECOS. N Engl J Med 306 (1982) 404-406
23. Kaunitz A.M. Oral contraceptive in perimenopause. Am J Obstet Gynecol 185 Suppl 2 (2001) S32-S37
24. Curtis K.M., and Martins S.L. Progestogen-only contraception and bone mineral density: a systematic review. Contraception 73 (2006) 470-487
25. Bahamondes L. Does the use of hormonal contraceptives affect bone mineral density?. Exp Rev Obstet Gynecol 2 (2007) 141-153
26. The Practice Committee of the American Society for Reproductive Medicine. The menopausal transition. Fertil Steril 86 Suppl 5 (2006) S253-S256
27. Harlow D.H., Cain K., Crawford S., et al. Evaluation of four proposed bleeding criteria for the onset of late menopausal transition. J Clin Endocrinol Metab 91 (2006) 3432-3438